EMA predicts drug shortages if third countries fail to meet new EU API rules
This article was originally published in SRA
Executive Summary
Some 50 drugs currently being marketed in the EU would clearly be at risk of shortage - and another 150 potentially at risk of shortage - if third country regulators fail to comply with requirements for active pharmaceutical ingredients that the EU falsified medicines legislation will introduce in July 20131.
You may also be interested in...
WHO Examines Ethical Criteria For Human Challenge Trials Ahead Of Next Health Emergency
The World Health Organization is looking to finalize its guidance on the ethical criteria that should be applied to studies that involve deliberately infecting healthy individuals to speed up research.
EU Consults On What Constitutes Personal & Commercially Confidential Data In Marketing Applications
Based on their experience with dealing with requests for access to documents over the past 12 years, EU regulators have proposed updating their guideline that provides for a harmonized approach to protecting personal data and business secrets in marketing authorization applications.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.